

Figure S3 BrdU pre-treatment changes sensitivity to mutagens (refer to Figure 6). **A, B.** Cells were untreated (untrt) or pre-treated (+BrdU) with 32.6 µM BrdU (2h at 32°C), and then spotted onto drug plates (YES), 1/5 dilutions. Arrows indicate greater sensitivity to drug +BrdU. Refer to Figure 6A for control. **A**. Sensitivity to UV, irradiated after plating yeast. **B.** Sensitivity to MMS after BrdU treatment. **C.** Analysis of can1$^-$ isolates from forward mutation study. Strains were pooled to assess *can1* amplification and RFLP ±BrdU; no differences were seen between genotypes. The *can1* locus was amplified by PCR, and produces a 3.2 kb band by agarose gel electrophoresis. PCR product was digested with EcoRI, producing 4 restriction fragments which were screened on 8% TBE-PAGE gels. Lane 1 (top) is a negative (water) control for PCR. Lanes 2 and 3 are non-incorporating strains that were known *can1*$^+$ or *can1-1* genotypes. Restriction fragment length differences were not detected in any of the can1- isolates. Instead, a minority of BrdU-treated isolates failed to amplify a detectable *can1* band (8.6% of all BrdU treated isolates).